Ameloblastoma
Conditions
Interventions
Intervention Group:Drug: Dabrafenib
Manufacturer: Novartis Europharm Limited
Administration Method: Oral (PO)
Dosage and Frequency: 150 mg, twice daily (BID)
Drug: Trametinib
Manufacturer: Novartis Eu
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years; 2. Diagnosed with solid/multicystic type ameloblastoma with confirmed BRAF V600E mutation by next-generation sequencing (NGS); 3. Requires mandibular segmental resection at diagnosis, confirmed by two or more chief physicians; 4. No distant metastasis or malignancy; 5. ECOG score 0-1; 6. Willing to undergo surgery after induction therapy; 7. No significant contraindications to MEK and BRAF inhibitors; 8. Major organ function meets the following standards: a) Hematological: WBC >= 4.0×10^9/L, ANC >= 1.5×10^9/L, PLT >= 100×10^9/L, Hb >= 90g/L (no transfusion or blood products, no use of G-CSF or other hematopoietic stimulants within 14 days); b) Biochemical: Serum albumin >= 3.0 g/dL, TBIL = 60 ml/min; c) Coagulation: INR or PT <= 1.5×ULN (anticoagulant-treated subjects must have PT within the intended range); 9. Women of childbearing age must use effective contraception, have a negative pregnancy test within 7 days before enrollment, and agree to use effective contraception during the study and for 16 weeks after the last dose of trametinib and dabrafenib. Male subjects with partners of childbearing age must use effective contraception during the study and for 16 weeks after the last dose of trametinib and dabrafenib. 10. Voluntary participation with signed informed consent, good compliance, and cooperation for follow-up.
Exclusion criteria
Exclusion criteria: 1. Previous use of dabrafenib, trametinib, or other BRAF/MEK inhibitors; 2. Active autoimmune diseases (stable conditions not requiring systemic immunosuppression allowed); 3. Congenital or acquired immunodeficiency (e.g., HIV), active hepatitis B (HBV-DNA >= 10^4 copies/ml), or hepatitis C (positive HCV antibody and HCR-RNA above the detection limit); 4. Known allergy to study drugs or their excipients, or severe allergic reactions to other monoclonal antibodies or targeted drugs; 5. Myocardial infarction, severe/unstable angina, NYHA class II or higher heart failure, significant arrhythmias, or symptomatic congestive heart failure within 6 months before enrollment; 6. Live vaccination within 4 weeks before the first dose of study drugs (inactivated virus vaccines allowed for seasonal flu, but live attenuated intranasal vaccines not allowed); 7. History of allogeneic organ or hematopoietic stem cell transplantation; 8. Known history of substance abuse or drug addiction; 9. Pregnant or breastfeeding women; 10. Diagnosed with any other tumors within 5 years before the study, except for locally treatable and cured basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ, papillary thyroid carcinoma, and benign tumors; 11. Other severe physical or mental diseases or laboratory abnormalities that may increase the risk of participation or interfere with study results, deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor Volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological Response;Recurrence-Free Survival;Adverse reactions and safety of drugs;Osteogenic response after medication; | — |
Countries
China
Contacts
Public ContactWei CAO
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed